. ICRs have been reported to be highly expressed on cells 31 comprising the HIV reservoir 8, 9 , but are not discriminatory. Equally, CD2 was 32 reported to be enriched on latently infected cells, but is also widely expressed 33 on other T cells 10 . 34
35
Recently, CD32a (FcγRIIa) -a low affinity IgG receptor expressed on myeloid 36 cells and granulocytes, but not generally considered to be expressed on T 37 cells 11 -has been proposed as a specific surface marker for latent HIV 38 infection 12 . It is unclear whether this enrichment holds true in tissue 13 as well 39 as peripheral blood CD4 T cells, or whether there is differential expression in 40 resting memory cells which comprise a major part of the latent reservoir 9, 14, 15 . 41
Here we investigate CD32 expression on CD3+ CD4+ cells in the blood and 42 tissue of individuals treated during primary HIV infection (PHI) (a group of 43 interest due to an association with post treatment virological remission and a 44 more labile reservoir [16] [17] [18] ), and explore associations with cell phenotype, other 45
For participants on ART, the median percentage of CD4 T cells expressing 63 CD32 was 1.5% (range 0.24-6.4%; representative gating shown in Fig. 1a ; 64 further examples in Supplementary Fig. 1 ). This did not differ from pre-therapy 65 levels (median 1.4%; range 0.31-2.6%) or healthy controls (median 1.7%; 66 range 0.49-4.9%; Fig. 1b Table 2 ). Three individuals remained virologically suppressed 84 at the end of follow up after TI (median 197 weeks), all of whom had CD32+ 85 CD4% values below the median (Fig. 1e) . 86
87

CD32 expression on CD4 T cells is associated with a differentiated memory 88 phenotype 89
As CD4 T cells have not previously been considered to express CD32, little is 90 known about which CD4 T cells express this marker. We therefore compared 91 the memory phenotype of CD32+ and CD32-CD4 T cell subsets (as defined 92
in Fig. 2a ) during treated PHI. CD32+ CD4 T cells had lower proportions of 93 naïve and central memory (T CM ) T cells than their CD32-counterparts. In 94 contrast, transitional memory (T TM ), effector memory (T EM ) and T EMRA cells 95 comprised a greater portion of the CD32+ CD4 T cell pool than for CD32-96 CD4 T cells ( Fig. 2b ; all p<0.001), reflecting a more differentiated memory 97 phenotype. The same pattern was also observed in healthy controls (Fig. 2c)  98 and prior to ART initiation ( Supplementary Fig. 3) . 99
100
CD32 expressing CD4 T cells have high levels of immune checkpoint 101 receptors 102
The expression of PD-1, Tim-3 and TIGIT was elevated on CD32+ CD4 T 103 cells compared with CD32-counterparts, in both treated HIV+ individuals and 104 healthy controls (Figure 3a-d) , although without significant correlations 105 between ICR and CD32 expression ( Supplementary Fig. 4 ). Elevated 106 expression of all three ICRs on CD32+ CD4 T cells was also observed at 107 baseline ( Supplementary Fig. 5 ) and, for PD-1 and Tim-3, at higher levels 108 than after a year of ART. These ICRs are known to be variably expressed ondifferent CD4 memory subsets, with elevated expression on non-naïve T 110 cells 8, 9, 21 . Elevated PD-1, Tim-3 and TIGIT expression was observed even 111 when accounting for memory differentiation ( Supplementary Fig 6) number of input cells (as determined by albumin qPCR), by a previously 370 described assay 20, 36 . Where possible, PCRs were performed in triplicate 371 although due to the rare cell populations this was not possible for the sorted 372
CD32+ cells. 373
Statistical analysis 374
Continuous variables were compared between groups using non-parametric 375 tests throughout. Comparisons between CD32+ and CD32-populations were 376 performed using the Wilcoxon matched-pairs signed rank test. Where three 377 groups were compared, a Kruskal-Wallis test (unpaired data) or Friedman test 378 (paired data) was used; pairwise comparisons were performed on pre-379 determined combinations of groups only if the overall test p-value was <0.05. 380
Correlative analyses were performed using Spearman's rank correlation. Time 381 to viral rebound was assessed as time from treatment interruption to the first 382 of two consecutive VL measurements >400 copies/mL (the limit of detection 383 of the assay used at some trial sites). Individuals who did not rebound were 384 censored at the date of the last VL measurement. Time to viral rebound was 385 visualised with Kaplan-Meier curves stratified at the median and associations 386 examined using Cox proportional hazard models. For all tests, p values <0.05 387 were considered statistically significant. Analyses were performed using 388
GraphPad Prism (GraphPad Software, La Jolla, California, USA) version 6. 
